For example, the cobas epidermal growth factor receptor (EGFR) mutation test V2 (Roche) to detect EGFR mutations (Exon 19 deletion or exon 21 L858R substitution mutation) in non-small-cell lung cancer (NSCLC) patients for treatment with Tagrisso (osimertinib) and Tarceva (erlotinib) [16,17] (accessed on 9 January 2024). Here, EGFR is linked to non-small cell lung carcinoma.